Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial looked at a medicine called spesolimab as a treatment for palmoplantar pustulosis (PPP) — a skin condition that causes painful blisters and pustules on the palms of the hands and soles of the feet. A total of 152 people took part, divided into five groups: one group received a placebo (a dummy treatment with no active medicine), and four groups received different doses of spesolimab. The trial's main goal was to measure how much a scoring system called the PPP ASI — which rates the severity of the skin condition on a scale from 0 (no disease) to 72 (worst possible) — changed from the start of the trial to week 16. The reported data shows that all five groups, including the placebo group, had lower PPP ASI scores at week 16 compared to where they started. The placebo group's score decreased by about 33.6%, while the four spesolimab dose groups saw decreases of approximately 44.2%, 48.3%, 46.2%, and 38.9% respectively. For pain (measured on a scale of 0 to 10, where 0 means no pain and 10 means very severe pain), the reported data shows all groups also had lower pain scores at both week 4 and week 16 compared to baseline. Regarding the number of people whose PPP ASI score dropped by at least 50% by week 16, the reported data shows this occurred in 12 participants in the placebo group, compared to 7, 10, 12, and 18 participants across the four spesolimab dose groups. For a 75% drop in score, the numbers were 3 in the placebo group and 3, 6, 4, and 9 across the spesolimab groups. It is also worth noting that not everyone completed the trial — for example, 11 out of 43 people in the placebo group and 12 out of 44 in the highest-dose spesolimab group did not finish the study, though the reasons were not detailed in the reported data provided here. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 37731086) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Psoriasis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 18 and 75 years old at the time of screening
- You have been diagnosed with Palmoplantar Pustulosis (PPP), meaning you have had visible, non-infected blisters/pustules on your palms and/or soles for more than 3 months, with or without psoriasis on other parts of your body
- Your PPP is rated as at least "moderate" in severity based on a doctor's assessment at both screening and the start of the trial
- Your PPP scores at least 12 on a specific skin severity scale (called PPP ASI) at both screening and the start of the trial (confirm with trial site)
- You are male or female; if you are a woman who could become pregnant, you must be willing and able to use a highly effective form of contraception during the trial
- You are willing to sign a consent form agreeing to take part in the trial
Who may not be able to join:
- Women who are currently pregnant, breastfeeding, or planning to become pregnant during the trial
- People with serious, worsening, or poorly controlled conditions affecting the kidneys, liver, blood, hormones, lungs, heart, nervous system, brain, or mental health
- People who have a history of, or currently have, PPP-like disease that was triggered by a specific type of medication called anti-TNF drugs (confirm with trial site)
- People who have received an organ transplant (except a corneal/eye transplant received more than 12 weeks before screening) or have ever received stem cell therapy
- People with a known history of, or signs suggesting, diseases involving abnormal growth of lymph cells, such as lymphoma or swollen lymph nodes/spleen
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
The Percentage Change in Palmoplantar Pustulosis Area and Severity Index (PPP ASI) at Week 16 From Baseline
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.